Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC)
Eva Řezníčková, Soňa Krajčovičová, Miroslav Peřina, et al.
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114792-114792
Open Access | Times Cited: 22

Showing 22 citing articles:

Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 56
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
Yuming Zhang, Lianhai Shan, Wentao Tang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5185-5215
Closed Access | Times Cited: 14
Targeted Degradation of Cell‐Surface Proteins via Chaperone‐Mediated Autophagy by Using Peptide‐Conjugated Antibodies
Jinning Shao, Xuefen Lin, Haoting Wang, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 18
Closed Access | Times Cited: 9
Targeted degradation of extracellular secreted and membrane proteins
Xuankun Chen, Yaxian Zhou, Yuan Zhao, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 762-775
Open Access | Times Cited: 17
Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques
Siyu Chen, Jingliang Cui, Haiyan Chen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115911-115911
Closed Access | Times Cited: 17
The Molecular Context of Oxidant Stress Response in Cancer Establishes ALDH1A1 as a Critical Target: What This Means for Acute Myeloid Leukemia
Garrett M. Dancik, Lokman Varışlı, Spiros Vlahopoulos
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9372-9372
Open Access | Times Cited: 15
Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins
Melisa Halilovic, Mohamed Abdelsalam, Joanna Zabkiewicz, et al.
Leukemia (2024) Vol. 38, Iss. 12, pp. 2561-2572
Open Access | Times Cited: 5
PROTACS: A technology with a gold rush-like atmosphere
Yuwei Wang, Li Lan, Min Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115037-115037
Closed Access | Times Cited: 21
The application of PROTAC in HDAC
Shaoting Chen, Yuxiang Zheng, Benji Liang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115746-115746
Closed Access | Times Cited: 12
Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy
Tizhi Wu, Zhiming Zhang, Guangyue Gong, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115774-115774
Closed Access | Times Cited: 9
From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology
Xuyang Zhao, Yifan Chen, Huang Su, et al.
Deleted Journal (2023) Vol. 1, Iss. 2
Open Access | Times Cited: 7
Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer
Hui-Jun Nie, Benfu Li, Jingya Sun, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107876-107876
Closed Access | Times Cited: 2
Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia
Wenyan Liu, Yu Bai, Licheng Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115974-115974
Closed Access | Times Cited: 6
Targeted Degradation of Cell‐Surface Proteins via Chaperone‐Mediated Autophagy by Using Peptide‐Conjugated Antibodies
Jinning Shao, Xuefen Lin, Haoting Wang, et al.
Angewandte Chemie (2024) Vol. 136, Iss. 18
Closed Access | Times Cited: 1
PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives
Makenzie Vorderbruggen, Carlos A. Velázquez‐Martínez, Amarnath Natarajan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5067-5067
Open Access | Times Cited: 1
FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives
Heba M. Hesham, Eman M.E. Dokla, Eman Z. Elrazaz, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116717-116717
Closed Access | Times Cited: 1
Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges
Jan Rataj, Lukáš Górecki, Darina Muthná, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 182, pp. 117788-117788
Open Access | Times Cited: 1
New strategies to hit hematological cancers
Marilia Barreca, Francesco Bertoni, Paola Barraja
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116350-116350
Closed Access
PROTACs of cyclin-dependent kinases
Denisa Veselá, Eva Řezníčková, Václav Mik, et al.
Annual reports in medicinal chemistry (2024)
Closed Access
N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants
Xiuqi Wang, Rosa Anna DeFilippis, Yuet‐Kin Leung, et al.
Bioorganic Chemistry (2023) Vol. 143, pp. 106966-106966
Open Access | Times Cited: 1
Page 1

Scroll to top